top of page

Number of working groups found:

37

Cytogenetics

View Members

Germline Mutations

View Members

Research Correlatives

View Members

Tumor Board

View Members

Health Care Utilization/PHIS Financial Analysis

View Members

Bridging Therapy

View Members

Effect of Obesity

View Members

Prolonged Hematologic Toxicities

View Members

Expired CAR products

View Members

Harmonizing CAR Clinical Practice

View Members

"Pick the Winners"

View Members

Trisomy 21

View Members

Fludarabine Pharmacokinetics

View Members

Immune Reconstitution and Infection

View Members

Extramedullary Disease

View Members

Product Specifications

View Members

Machine Learning

View Members

Real-World Ino/Blina

View Members

CAR Toxicity

View Members

HSCT post-CAR (HSCT vs. Surveillance)

View Members

GVHD post-CAR

View Members

Commercial CAR for Lymphoma

View Members

Effect of Peripheral Blast count at Apheresis

View Members

Mediport use as an acceptable standard for CAR infusion

View Members

Microbiome

View Members

InO post-CART

View Members

Second Infusions

View Members

CAR Indication/Outcomes in 1st Relapse

View Members

MAP Outcomes

View Members

Race, Socioeconomics and Survivorship

View Members

Fate post-Relapse

View Members

Infant ALL

View Members
bottom of page